高级检索
当前位置: 首页 > 详情页

Clinical-Pathological Correlation of the Pathophysiology and Mechanism of Action of COVID-19-a Primer for Clinicians

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

单位: [1]Natl Univ Hlth Syst, Dept Otolaryngol Head & Neck Surg, Singapore, Singapore [2]Natl Univ Hlth Syst, Yong Loo Lin Sch Med, Dept Otolaryngol, 1E Kent Ridge Rd, Singapore 119228, Singapore [3]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Otolaryngol Head & Neck Surg, Wuhan, Peoples R China [4]Univ Barcelona, Hosp Clin Barcelona, Dept Otorhinolaryngol, Rhinol Unit & Smell Clin,IDIBAPS,CIBERES, Barcelona, Catalonia, Spain
出处:
ISSN:

关键词: COVID-19 Pandemic Epidemiology Pathogenesis Pathophysiology Mechanism of action

摘要:
Purpose of Review Increasing knowledge of the pathogenesis of the SARS-CoV-2 infection and the complex interaction between host and viral factors have allowed clinicians to stratify the severity of COVID-19 infection. Epidemiological data has also helped to model viral carriage and infectivity. This review presents a comprehensive summary of the pathophysiology of COVID-19, the mechanisms of action of the SARS-CoV-2 virus, and the correlation with the clinical and biochemical characteristics of the disease. Recent Findings ACE2 and TMPRSS2 receptors have emerged as a key player in the mechanism of infection of SARS-CoV-2. Their distribution throughout the body has been shown to impact the organ-specific manifestations of COVID-19. The immune-evasive and subsequently immunoregulative properties of SARS-CoV-2 are also shown to be implicated in disease proliferation and progression. Information gleaned from the virological properties of SARS-CoV-2 is consistent with and reflects the clinical behavior of the COVID-19 infection. Further study of specific clinical phenotypes and severity classes of COVID-19 may assist in the development of targeted therapeutics to halt progression of disease from mild to moderate-severe. As the understanding of the pathophysiology and mechanism of action of SARS-CoV-2 continues to grow, it is our hope that better and more effective treatment options continue to emerge.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2020]版
大类 | 3 区 医学
小类 | 3 区 免疫学 4 区 过敏
最新[2025]版
大类 | 2 区 医学
小类 | 2 区 过敏 2 区 免疫学
JCR分区:
出版当年[2019]版:
Q2 ALLERGY Q2 IMMUNOLOGY
最新[2023]版:
Q1 ALLERGY Q1 IMMUNOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2019版] 出版当年五年平均 出版前一年[2018版] 出版后一年[2020版]

第一作者:
第一作者单位: [1]Natl Univ Hlth Syst, Dept Otolaryngol Head & Neck Surg, Singapore, Singapore
通讯作者:
通讯机构: [1]Natl Univ Hlth Syst, Dept Otolaryngol Head & Neck Surg, Singapore, Singapore [2]Natl Univ Hlth Syst, Yong Loo Lin Sch Med, Dept Otolaryngol, 1E Kent Ridge Rd, Singapore 119228, Singapore
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:426 今日访问量:2 总访问量:410 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)